AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-60. (cancelled):

61. (currently amended): A method for the preparation of microparticles from a liquid one-phase system containing biological material and a suitable amount of at least two compounds being incompatible in aqueous solution, ~~wherein the formation of the microparticles is achieved by evaporation of~~ the method consisting of the method step of evaporating water from the one-phase system leading to a phase separation with a dispersed phase and a continuous phase, thereby producing the formation of the microparticles, wherein the first compound of the at least two compounds is a dextran-based polymer, and the second compound of the at least two compounds is a polyaliphatic alcohol or derivative thereof, and wherein the evaporating step does not employ any emulsification means, vortexing step, or stirring step.

62. (currently amended): A method according to claim 61, wherein said evaporating ~~process~~ step has a duration between 0.1 and 100 hours.

63. (currently amended): A method according to claim 61, wherein said evaporating ~~process~~ step has a duration between 0.1 and 50 hours.

64. (currently amended): A method according to claim 61, wherein said evaporating ~~process~~ step is carried out at a temperature between 0 °C and 100 °C.

65. (currently amended): A method according to claim 61, wherein said evaporating ~~process~~ step is carried out at a temperature between 0 °C and 50 °C.

66. (currently amended): A method according to claim 61, wherein said evaporating ~~process~~ step is carried out under a pressure of 0.1 to 760 mm Hg p.

67. (currently amended): A method according to claim 61, wherein said evaporating ~~process~~ step is stopped when the water concentration within the system is between 5 to 80 %.

68. (currently amended): A method according to claim 61, wherein said evaporating ~~process~~ step is stopped when the water concentration within the system is between 5 to 75 %.

69. (previously presented): A method according to claim 63, wherein the calcium phosphate precipitation method is used.

70. (previously presented): A method according to claim 65, wherein the calcium phosphate precipitation method is used.

71. (currently amended): A method according to claim 67, wherein the calcium phosphate precipitation method is used.

72. (currently amended): A composition to produce particles for delivery of biological material into a target cell comprising:

biological material,

a preparation of an aqueous polymer system on the basis of a mixture with at least two compounds being incompatible in aqueous solutions, said compounds being present in a

concentration in water that leads to the spontaneous formation of a dispersed phase by one of said compounds, said dispersed phase including microparticles composed of at least 75 % of said polymer compounds and 25 % or less of said biological material in said aqueous solution, wherein said microparticles are produced by the process of claim 61.

73. (previously presented A composition according to claim 72, wherein the mixture is a water mixture.

Cancel claims 74-77.

78. (previously presented): A composition according to claim 77, wherein one compound is substituted by a nucleic acid-binding agent.

79. (previously presented): A composition according to claim 77, wherein one compound is substituted by a nucleic acid-binding agent.

80. (currently amended): A composition according to claim 72~~75~~, wherein the polyaliphatic alcohol is polyethylene oxide, or a derivative thereof, or polyethylene glycol (PEG), or PEG-acrylate, or polyvinyl acetate, or a derivative thereof.

81. (previously presented): A composition according to claim 80, wherein said polyethyleneglycol has a molecular weight from 3 kDa to 20 kDa.

82. (previously presented): A composition according to claim 72, wherein said composition comprises a surfactant or a derivative thereof.

83. (previously presented): A composition according to claim 82, wherein said surfactant is polyoxyethylene sorbitan and a fatty acid ether (Tween-20, 40, 60, 80).

84. (previously presented): A composition according to claim 72, said composition comprising polyoxyethylene-polyoxypropylene co-polymer.

85. (previously presented): A composition according to claim 84, wherein said polyoxyethylene-polyoxypropylene co-polymer is Pluronic L-64 or Pluronic F-68, or a derivative thereof.

86. (previously presented): A composition according to claim 72, said composition comprising polyvinylpyrrolidone (PVP).

87. (previously presented): A composition according to claim 72, wherein said biological material comprises polynucleotides, or vaccines (microbes, viruses), or proteins, or peptides, or derivatives thereof.

88. (previously presented): A composition according to claim 72, wherein said biological material comprises cytokines or monoclonal antibodies.

89. (previously presented): A composition according to claim 88, wherein said cytokines comprise interferones and/or interleukines.

Cancel claims 90-94.

95. (previously presented): A composition according to claim 87, wherein said polynucleotide is DNA.

96. (previously presented): A composition according to claim 87, wherein said polynucleotide is RNA.

97. (previously presented): A composition according to claim 96, wherein said RNA is antisense.

98. (previously presented): A composition according to claim 80, wherein said polyethylene glycol has a molecular weight from 1 kDa to 20 kDa.

99. (previously presented): Microparticles formed by conducting a method as in any one of claims 61 to 71.

100. (previously presented): Microparticles according to claim 99 being composed of at least 75 % polymer molecules and 25 % or less biological material.